Phase 3 N=64 IGIV Study for Chronic ITP Patients Ages 3-70
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=66 A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Primary: Number of Participants With Adverse Events — 64; 19; 2; 1 Participants
Phase 2 N=122 A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR) — 43.5 percentage of participants
N/A N=326 Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Number of Participants Utilizing Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Therapies for First-line Treatment — 128; 37; 3; 11 Participants
Phase 3 N=34 A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
Idiopathic Thrombocytopenic Purpura
Primary: Achievement Rate of Stable Platelet Response — 36.4; 0.0 Percentage of participants — p=0.030
Phase 3 N=57 Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10
Immune Thrombocytopenic Purpura
Primary: Platelet Response — 80.7 Percent of participants
Phase 3 N=18 Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura
Immune (Idiopathic) Thrombocytopenic Purpura
Primary: Responder Patients — 72.2 percentage of subjects
Phase 4 N=162 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Purpura, Thrombocytopaenic, Idiopathic
Primary: Number of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at Baseline — 150; 9; 0; 0 Participants
Phase 3 N=203 Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia
Primary: Percentage of Time With a Platelet Response During the First 6 Months of Treatment — 50.00 percentage of time
Phase 3 N=103 A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants With a Sustained Response — 36; 63 percentage of participants — p=0.004
Phase 3 N=62 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Percentage of Participants With a Durable Platelet Response — 10.0; 52.4 percentage of participants — p=0.0018
Phase 3 N=92 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1 — 1; 25 Participants…
Phase 3 N=34 P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
Idiopathic Thrombocytopenic Purpura
Primary: Weeks With Weekly Platelet Response — 0.0; 11.0 Weeks — p=<0.0001
Phase 2 N=19 Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Primary: Incidence of the Composite Primary Outcome of Exacerbation or Refractory TTP — 2; 0 Participants
Phase 4 N=57 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)
Immune Thrombocytopenic Purpura
Primary: Set of Antibodies Most Frequently Bound to Red Blood Cells (RBCs) in Subjects Experiencing Clinically Significant Intravascular Hemolysis
Phase 3 N=234 Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Number of Participants With Splenectomy During 52-Week Treatment Period — 28; 14; 49; 143 Participants — p=<0.0001
N/A N=28 Sepsis-Associated Purpura Fulminans International Registry - Europe
Sepsis
Primary: Mortality — 11 Participants
Phase 3 N=23 Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Chronic Idiopathic Thrombocytopenic Purpura · Purpura, Thrombocytopenic, Idiopathic
Primary: Number of Responders at Week 6 — 9; 0; 6; 8 Participants
Phase 3 N=197 RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
Purpura, Thrombocytopaenic, Idiopathic
Primary: Percentage of Responders — 2; 1; 7; 37 Percentage of participants — p=<0.001
Phase 3 N=145 Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time to Platelet Count Response — 2.69; 2.88 days — p== 0.0099
Phase 1 N=24 Thrombosomes® in Bleeding Thrombocytopenic Patients
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Phase 2 N=16 Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 7; 1 Participants
Phase 3 N=116 Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults
Immune Thrombocytopenic Purpura
Primary: Percentage of Participants With a Clinical Response — 80.0 Percentage of participants
Phase 2 N=41 A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading…
Phase 2 N=15 Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Purpura, Thrombocytopaenic, Idiopathic
Primary: Percentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of…
Phase 3 N=35 A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Chronic Idiopathic Thrombocytopenic Purpura
Primary: The Number of Subjects With Chronic ITP Treated With Gammaplex Whose Platelet Count Reached a Threshold of 50 x 10^9/L. — 29 participants
Phase 2 N=66 Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)
Purpura, Thrombocytopaenic, Idiopathic
Primary: Number of Participants Who Responded (Platelet Count >=50 Gi/L and >=2x Baseline) to Eltrombopag Treatment in Cycle 2 or Cycle 3 Given Participants Responded in Cycle 1…
Phase 3 N=51 Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Primary: Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study Period — 93.5 percentage of participants
Phase 2 N=75 Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
Idiopathic Thrombocytopenic Purpura
Primary: Number of Months With Platelet Response During the 12-Month Treatment Period — 9.2 months
Phase 3 N=407 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenic Purpura
Primary: Adverse Events — 162; 215 participants